Synedgen uses the science of glycomics – the study of complex sugar structure and function – to discover and develop ultra-purified therapeutic polysaccharides that are soluble, active, and targeted in the human body. Our new molecular entities are designed to alter the progression of diseases and improve the lives of patients.
October 10, 2018
Synedgen Announces the Launch of Moisyn Rinse to Treat Dry Mouth
September 19, 2018
Synedgen Appoints Kaveri Parker, Ph.D. as Chief Business Officer
July 11, 2018
Prisyna Announces Publication of Research Demonstrating Synvaza’s Effect on Oral Lesion Relief